Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma - Quiz - MDSpire

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

  • By

  • Yetian Dong

  • Tingting Yang

  • Mengyu Zhao

  • Fengmei Song

  • Rongrong Chen

  • Mingming Zhang

  • Ruimin Hong

  • Jingjing Feng

  • Shan Fu

  • Pingnan Xiao

  • Huijun Xu

  • Jiazhen Cui

  • Simao Huang

  • Guoqing Wei

  • Alex H. Chang

  • He Huang

  • Yongxian Hu

  • August 20, 2025

  • 0 min

Share

Original Source(s)

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

  • by Yetian Dong, Tingting Yang, Mengyu Zhao, Fengmei Song, Rongrong Chen, Mingming Zhang, Ruimin Hong, Jingjing Feng, Shan Fu, Pingnan Xiao, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Chang, He Huang, Yongxian Hu

  • August 20, 2025

Related Content

HDAC7 controls anti-viral and anti-tumor immunity by CD8+ T cells

Epstein-Barr virus associated diseases: Immune alterations and targeted approaches

Trends and Key Areas of Research on Artificial Intelligence in Lymphoma: A Bibliometric Study from 2010 to 2024